Active ShortageTier 3 — Critical

CEFAZOLIN INJECTION, USP

BAXTER CORPORATION

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of CEFAZOLIN INJECTION, USP in Canada?

Yes. CEFAZOLIN INJECTION, USP 20MG has an active shortage reported to Health Canada (last updated November 19, 2025).

Why is CEFAZOLIN INJECTION, USP not available?

The reason the manufacturer reported: Shortage of an active ingredient.

When will CEFAZOLIN INJECTION, USP be available again?

No estimated resolution date has been reported yet. Follow this page to get an email as soon as the status changes.

Can I still get this?Check with your pharmacist — only products with a different form or route found

StatusActive Shortage

Same-ingredient products on file4 products · 0 same form & route

Affected strength20MG

Report last updated2025-11-19

Checked by MedShort2026-11-12

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Other Products

CEFAZOLIN FOR INJECTION

TEVA CANADA LIMITED

1G · DIN 02108127

Different strengthDifferent dosage formSame routeNo current shortage

Compare these two →

CEFAZOLIN FOR INJECTION, USP

FRESENIUS KABI CANADA LTD

1G · DIN 02237138

Different strengthDifferent dosage formSame routeNo current shortage

Compare these two →

CEFAZOLIN SODIUM FOR INJECTION BP

STERIMAX INC

10G · DIN 02465477

Different strengthDifferent dosage formSame routeNo current shortage

Compare these two →

CEFAZOLIN FOR INJECTION USP

SANDOZ CANADA INCORPORATED

500MG · DIN 02308932

Different strengthDifferent dosage formDifferent routeNo current shortage

Compare these two →

What this means

Does this mean my pharmacy is out of stock?

Not necessarily — a national shortage doesn't mean every pharmacy has run out. Some locations may still have stock, especially of a specific strength or pack size.

What should I do?

Health Canada classes this as a Tier 3 shortage, its highest-impact category. If you rely on this medication, talk to your pharmacist or care team now rather than waiting for your supply to run low. This product is usually given in a hospital or clinic, where the pharmacy team manages supply. If you're scheduled to receive it, ask your care team.

Have you checked a pharmacy recently?

No community reports yet — be the first to share what you found.

Community reports are not verified by a pharmacy and may reflect a small sample size. This is not a guarantee of current stock.

DIN

02496313

Strength

20MG

Dosage Form

SOLUTION

Route

INTRAVENOUS

Active Ingredient

CEFAZOLIN

Tier

Tier 3 — Critical

Last Updated

2025-11-19

Reason for Shortage

Shortage of an active ingredient.

Source

View original report on healthproductshortages.ca ↗

Past Reports for This Drug

CEFAZOLIN INJECTION, USP has 2 shortage/discontinuation reports on file — this is one of them.

2025-11-19

Active Shortage

Shortage of an active ingredient.

Other Products from BAXTER CORPORATION

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

(20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP

DIN 00438014

(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786292

(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP

DIN 00438049

(20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786209

(20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP

DIN 00437999

(40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786217